RO7234292 (RG6042)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntingtons Disease
Conditions
Huntingtons Disease
Trial Timeline
Sep 2, 2019 → Jan 18, 2022
NCT ID
NCT04000594About RO7234292 (RG6042)
RO7234292 (RG6042) is a phase 1 stage product being developed by Roche for Huntingtons Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04000594. Target conditions include Huntingtons Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04000594 | Phase 1 | Completed |
| NCT03842969 | Phase 3 | Completed |
| NCT03342053 | Phase 2 | Completed |
Competing Products
1 competing product in Huntingtons Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7234292 + Placebo | Roche | Phase 3 | 77 |